1. Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-19
- Author
-
Gormez, S., Gumusel, H. K., Ekicibasi, E., Degirmencioglu, A., Paudel, A., Akan, G., Atalar, F., Erdim, R., Eroglu, E., Dagdelen, S., Sariguzel, N., Kirisoglu, C. E., Pamukcu, B., and Acibadem University Dspace
- Subjects
SARS-CoV-2 ,D-dimer ,COVID-19 ,antithrombotic therapy ,enoxaparin ,low-molecular-weight heparin ,thrombosis - Abstract
OBJECTIVES: Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission. BACKGROUND: Coronavirus disease-2019 (COVID-19) predisposes patients to arterial and venous thrombosis. METHODS: In this retrospective, multicentre and observational study we analysed the data of 308 confirmed COVID-19 patients with normal D-dimer levels at initial admission. After propensity score matching (PSM) patients were grouped
- Published
- 2021
- Full Text
- View/download PDF